(Q53185401)

English

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

scientific article published on 22 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

genetic variation

1 reference

based on heuristic

inferred from title

1

object named as

A Tefferi

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

8

object named as

M R Litzow

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

author name string

T L Lasho

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

M M Patnaik

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

C M Finke

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

K Hussein

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

W J Hogan

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

M A Elliott

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

C A Hanson

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

A Pardanani

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

publication date

22 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

24

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

105-109

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

https://scigraph.springernature.com/pub.10.1038/leu.2009.225

0 references

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.225

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53185401&oldid=2139137193"